According to Poseida Therapeutics's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 4.75712. At the end of 2023 the company had a P/S ratio of 4.97.
Year | P/S ratio | Change |
---|---|---|
2023 | 4.97 | 42.25% |
2022 | 3.49 | -74.39% |
2021 | 13.6 | |
2020 | N/A |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
ORIC Pharmaceuticals
ORIC | N/A | N/A | ๐บ๐ธ USA |